RecruitingPhase 1NCT06056752

QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Studying Burkitt lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Anhui Provincial Hospital
Principal Investigator
Xiaoyu Zhu, Ph.D
Director of Hematology Department, Anhui Provincial Hospital
Intervention
QH103 Cell Injection(biological)
Enrollment
10 target
Eligibility
14 years · All sexes
Timeline
2023 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06056752 on ClinicalTrials.gov

Other trials for Burkitt lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Burkitt lymphoma →

← Back to all trials